International Journal of Medical Laboratory Research (IJMLR)

GLIMEPIRIDE-INDUCED LEUKOCYTOCLASTIC VASCULITIS: A RARE CASE REPORT AND INSIGHT OF THE 1990 ACR CRITERIA FOR THE DIAGNOSIS OF LEUKOCYTOCLASTIC VASCULITIS

​

Soumik Chatterjee, Papiya Majumdar, Barnali Dutta

​

ABSTRACT: Cutaneous drug-induced leukocytoclastic vasculitis accounts for about 10% of all vasculitis cases and usually presents as skin lesions in a palpable purpuric form that likely begins within two weeks after exposure to a particular agent. The use of glimepiride has recently increased with the sharp augmentation of poorly-controlled diabetes mellitus cases, and hence, recognition of this reaction is important as it may lead to fatal consequences, and discontinuation of the offending drug is a cornerstone of the management. To the best of our knowledge, this is the first reported case of Glimepiride-induced leukocytoclastic vasculitis from the Eastern Part of India.

​

KEYWORDS:Diabetes, Glimepiride, Leukocytoclastic vasculitis

​

REFERENCES:​

1. Genuth S. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care. 2015;38,1:170-5.

2. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51 Suppl 3: S368-76.

3. Calabrese, L.H., Michel, B.A., Bloch, D.A., Arend, W.P., Edworthy, S.M., Fauci, A.S., Fries, J.F., Hunder, G.G., Leavitt, R.Y., Lie, J.T., Lightfoot, R.W., Jr, Masi, A.T., McShane, D.J., Mills, J.A., Stevens, M.B., Wallace, S.L. and Zvaifler, N.J. (1990), The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis & Rheumatism, 33: 1108-1113.

4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239–45.

5. Basit A, Riaz M, Fawwad A. Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag. 2012; 8:463-72. Erratum in: Vasc Health Risk Manag. 2013; 9:1.

6. Trerattanavong K, Tadi P. Glimepiride. [Updated 2023 Jul 4]. In: StatPearls [Internet].

7. Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001 ;103,25:3111-6.

8. Baigrie D, Crane JS. Leukocytoclastic Vasculitis. [Updated 2023 Aug 8]. In: StatPearls [Internet].

9. Carlson JA (2010) The histological assessment of cutaneous vas- culitis. Histopathology 56.1:3–23

10. Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med. 2021;16,4:831-841.

11. Bouiller K, Audia S, Devilliers H, Collet E, Aubriot MH, Leguy-Seguin V, et al. Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: a retrospective study in 112 patients. Med (United States) 2016;95,28: e4238.